Martin E. Blackstein

10.4k total citations · 2 hit papers
101 papers, 6.3k citations indexed

About

Martin E. Blackstein is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, Martin E. Blackstein has authored 101 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Pulmonary and Respiratory Medicine, 43 papers in Oncology and 25 papers in Gastroenterology. Recurrent topics in Martin E. Blackstein's work include Sarcoma Diagnosis and Treatment (43 papers), Gastrointestinal Tumor Research and Treatment (25 papers) and Gastric Cancer Management and Outcomes (13 papers). Martin E. Blackstein is often cited by papers focused on Sarcoma Diagnosis and Treatment (43 papers), Gastrointestinal Tumor Research and Treatment (25 papers) and Gastric Cancer Management and Outcomes (13 papers). Martin E. Blackstein collaborates with scholars based in Canada, United States and France. Martin E. Blackstein's co-authors include George D. Demetri, Michael C. Heinrich, Paolo G. Casali, Manisha H. Shah, Charles M. Baum, Grant A. McArthur, Christopher R. Garrett, Ian Judson, Jaap Verweij and Xin Huang and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Martin E. Blackstein

98 papers receiving 6.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

2006 1.9k citations George D. Demetri, Allan T. van Oosterom et al. The Lancet profile →
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

2009 966 citations Ronald P. DeMatteo, Karla V. Ballman et al. The Lancet profile →

Peers

Countries citing papers authored by Martin E. Blackstein

Since Specialization

Citations

This map shows the geographic impact of Martin E. Blackstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin E. Blackstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin E. Blackstein more than expected).

Fields of papers citing papers by Martin E. Blackstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin E. Blackstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin E. Blackstein. The network helps show where Martin E. Blackstein may publish in the future.

Co-authorship network of co-authors of Martin E. Blackstein

This figure shows the co-authorship network connecting the top 25 collaborators of Martin E. Blackstein. A scholar is included among the top collaborators of Martin E. Blackstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin E. Blackstein. Martin E. Blackstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical features and outcomes of 20 patients with abdominopelvic desmoplastic small round cell tumor 2016 ·European Journal of Surgical Oncology ·Fernando A. Angarita, Saima Hassan, Amanda J. Cannell, Brendan C. Dickson, Rebecca A. Gladdy, Carol J. Swallow, Abha A. Gupta, Martin E. Blackstein, J. Andrea McCart	12
2	The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours 2015 ·European Journal of Cancer ·Carlos H. Barrios, Martin E. Blackstein, Jean‐Yves Blay, Paolo G. Casali, Matías Chacón, Jin Gu, Yoon‐Koo Kang, Toshirou Nishida, Das Purkayastha, Richard C. Woodman, Peter Reichardt	25
3	Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial 2014 ·Journal of Clinical Oncology ·Christopher L. Corless, Karla V. Ballman, Cristina R. Antonescu, (unknown), Robert G. Maki, Peter W. T. Pisters, Martin E. Blackstein, Charles D. Blanke, George D. Demetri, Michael C. Heinrich, Margaret von Mehren, Shreyaskumar Patel, Martin D. McCarter, Kouros Owzar, Ronald P. DeMatteo	210
4	Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors 2010 ·Cancer ·Jean‐Yves Blay, Margaret von Mehren, Martin E. Blackstein	51
5	Painful palatal swelling 2010 ·The Lancet ·Hagen Klieb, (unknown), (unknown), Iona Leong, Martin E. Blackstein	1
6	Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure 2009 ·Clinical Cancer Research ·Samuel E. DePrimo, Xin Huang, Martin E. Blackstein, Christopher R. Garrett, Charles S. Harmon, Patrick Schöffski, Manisha H. Shah, Jaap Verweij, Charles M. Baum, George D. Demetri	38
7	Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial breakdown → 2009 ·The Lancet ·Ronald P. DeMatteo, Karla V. Ballman, Cristina R. Antonescu, Robert G. Maki, Peter W. T. Pisters, George D. Demetri, Martin E. Blackstein, Charles D. Blanke, Margaret von Mehren, Murray F. Brennan, Shreyaskumar Patel, Martin D. McCarter, Jonathan Polikoff, Benjamin Tan, Kouros Owzar	966
8	Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases 2009 ·Annals of Oncology ·(unknown), Anthony M. Griffin, Melania Pintilie, Martin E. Blackstein	153
9	The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: The example of sunitinib for gastrointestinal stromal tumour 2008 ·European Journal of Cancer ·Isabelle Chabot, Jacques LeLorier, Martin E. Blackstein	27
10	Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial breakdown → 2006 ·The Lancet ·George D. Demetri, Allan T. van Oosterom, Christopher R. Garrett, Martin E. Blackstein, Manisha H. Shah, Jaap Verweij, Grant A. McArthur, Ian Judson, Michael C. Heinrich, Jeffrey A. Morgan, Jayesh Desai, Christopher D.�M. Fletcher, Suzanne George, Carlo L. Bello, Xin Huang, Charles M. Baum, Paolo G. Casali	1930
11	A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma 2006 ·Sarcoma ·Don Morris, Vivien Bramwell, Robert Turcotte, A Figueredo, Martin E. Blackstein, (unknown), S. Matthews, Elizabeth A. Eisenhauer	30
12	Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial 2004 ·Lung Cancer ·Ronald L. Burkes, Frances A. Shepherd, Martin E. Blackstein, (unknown), Paul F. Waters, G. Alexander Patterson, Thomas R.J. Todd, F. Griffith Pearson, Donald P. Jones, (unknown), (unknown), Robert J. Ginsberg	21
13	Lymph Node Metastasis in Soft Tissue Sarcoma in an Extremity 2004 ·Clinical Orthopaedics and Related Research ·Soha Riad, Anthony M. Griffin, Boaz Liberman, Martin E. Blackstein, Charles Catton, Rita A. Kandel, (unknown), Lawrence M. White, Robert S. Bell, Peter C. Ferguson, Jay S. Wunder	125
14	Bone marrow metastasis of angiosarcoma 2004 ·Pathology - Research and Practice ·Chen Wang, (unknown), Martin E. Blackstein, Robert H. Riddell	19
15	Gastrointestinal Stromal Tumours: Etiology, Pathology and Clinical Management 2004 ·Canadian Journal of Gastroenterology and Hepatology ·Martin E. Blackstein, Pierre Dubé, Jonathan A. Fletcher, (unknown), Margaret A. Knowling, Richard Létourneau, Donald G. Morris, Robert H. Riddell, (unknown), Carol J. Swallow	9
16	Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial 2002 ·Oncology ·Martin E. Blackstein, C. L. Vogel, (unknown), (unknown), José Iglesias, Allen S. Melemed	131
17	Extended follow-up of patients treated with cytotoxic chemotherapy for intra-abdominal desmoid tumors 2001 ·Diseases of the Colon & Rectum ·Lisa S. Poritz, Martin E. Blackstein, T. Berk, (unknown), Robin S. McLeod, Zane Cohen	40
18	Chemotherapy for desmoid tumors in association with familial adenomatous polyposis 1997 ·Diseases of the Colon & Rectum ·Mark A. Schnitzler, Zane Cohen, Martin E. Blackstein, Terri Berk, (unknown), Lisa Madlensky, (unknown)	55
19	Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial. 1992 ·Journal of Clinical Oncology ·Ronald L. Burkes, Robert J. Ginsberg, Frances A. Shepherd, Martin E. Blackstein, Melvyn Goldberg, Paul F. Waters, G. Alexander Patterson, T Todd, F.G. Pearson, (unknown)	162
20	Treatment of primary hepatocellular carcinoma by hepatic arterial infusion of 4'-epirubicin 1990 ·Frances A. Shepherd, Lorne Rotstein, Martin E. Blackstein, Ronald L. Burkes, Charles Erlichman, N. Iscoe, (unknown), K. Paul, P Mah	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact